Keros Therapeutics Files Proxy Statement Supplement
Ticker: KROS · Form: DEFA14A · Filed: May 19, 2025 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | DEFA14A |
| Filed Date | May 19, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, sec-filing
TL;DR
Keros filed proxy docs, nothing new for traders yet.
AI Summary
Keros Therapeutics, Inc. filed a Definitive Additional Materials filing (DEFA14A) on May 19, 2025, as a supplement to its Proxy Statement for the 2025 Annual Meeting of Stockholders. This filing is related to the company's proxy materials and does not appear to contain new proposals or significant financial updates beyond its role as a supplementary document.
Why It Matters
This filing is a procedural update to the company's proxy materials for its annual meeting, ensuring all necessary information is available to shareholders for voting.
Risk Assessment
Risk Level: low — This filing is a routine supplement to proxy materials and does not introduce new financial risks or significant strategic changes.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- 0001104659-25-050243 (filing_id) — Accession Number
- 20250519 (date) — Filing Date
FAQ
What is the purpose of this DEFA14A filing?
This DEFA14A filing serves as a supplement to the Notice of Annual Meeting of Stockholders and Proxy Statement for Keros Therapeutics, Inc.'s 2025 Annual Meeting.
When was this filing submitted to the SEC?
The filing was submitted on May 19, 2025.
Is this a preliminary or definitive proxy statement?
This filing is marked as 'Definitive Additional Materials' and is a supplement to the definitive proxy statement.
What is the company's Central Index Key (CIK)?
Keros Therapeutics, Inc.'s Central Index Key is 0001664710.
What is the company's business address?
The business address for Keros Therapeutics, Inc. is 1050 Waltham Street, Suite 302, Lexington, MA 02421.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on May 19, 2025 regarding Keros Therapeutics, Inc. (KROS).